All In Biotech

Drug Trial Radar · NCT01064401

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,841 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,841

Actual

Start

May 2010

Primary completion

Mar 2014

Study completion Jul 2014

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie
First posted
Feb 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis. The secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • BIIB019 (Daclizumab High Yield Process)Biological

    Daclizumab High Yield Process for subcutaneous injection

  • Interferon beta-1a PlaceboDrug

    Placebo to interferon beta-1a intramuscular injection

  • Interferon beta-1aBiological

    Interferon beta-1a for intramuscular injection

  • Daclizumab High Yield Process PlaceboDrug

    Placebo to Daclizumab High Yield Process subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Annualized Relapse Rate (ARR)Time frame: Up to 144 weeks

Locations

228 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    La Jolla, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Naples, Florida

  • Research Site

    Pompano Beach, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Sunrise, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Evanston, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Des Moines, Iowa

  • Research Site

    Kansas City, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Worchester, Massachusetts

  • Research Site

    Clinton Township, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Lebanon, New Hampshire

  • Research Site

    New Brunswick, New Jersey

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Buffalo, New York

  • Research Site

    Latham, New York

  • Research Site

    New York, New York

  • Research Site

    Rochester, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Medford, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Allentown, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Providence, Rhode Island

  • Research Site

    Franklin, Tennessee

  • Research Site

    Knoxville, Tennessee

Showing 40 of 228 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.